	Age - London (years; median, IQR)	Age - Johannesburg (years; median, IQR)	Height - London (meters; median, IQR)	Height - Johannesburg (meters; median, IQR)	BMI - London (kg/m^2; median, IQR)	BMI - Johannesburg (kg/m^2; median, IQR)	Waist:Hip ratio - London (Males; median, IQR)	Waist:Hip ratio - Johannesburg (Males; median, IQR)	Waist:Hip ratio - London (Females; median, IQR)	Waist:Hip ratio - Johannesburg (Females; median, IQR)	F:M ratio - London	F:M ratio - Johannesburg	NRS (median, IQR) - London	DAPOS (median, IQR) - London	BPI (median, IQR) - London	ISI (median, IQR) - London
All	51 (45, 56)	45.21 (39.76, 49.79)	1.72 (1.71, 1.80)	1.56 (1.52, 1.62)	26.37 (22.88, 29.24)	26.49 (23.01, 30.11)	0.96 (0.91, 1.01)	0.94 (0.88, 0.97)	0.89 (0.87, 0.93)	0.87 (0.83, 0.91)	0.43	5.26	2.5 (0,7)	23.5 (19, 30)	10 (1, 24)	11 (3.5, 17.5)
CHANT-ve	47 (32, 53)	41.14 (35.60, 47.22)	1.73 (1.66, 1.79)	1.54 (1.5, 1.66)	25.78 (23.76, 28.89)	26.92 (23.19, 30.39)	0.95 (0.90, 0.97)	0.93 (0.93, 0.95)	0.89 (0.85, 0.90)	0.87 (0.85, 0.89)	0.54	4.76	0 (0, 3)	25 (16.5, 30)	2 (0, 9)	6 (0, 16)
CHANT+ve	55.5 (48, 61)	46.66 (41.59, 51.92)	1.74 (1.68, 1.83)	1.57 (1.54, 1.62)	26.08 (22.89, 29.24)	28.04 (23.24, 35.34)	0.99 (0.91, 1.05)	0.95 (0.85, 1.04)	0.92 (0.88, 1.04)	0.87 (0.82, 0.91)	0.30	5.56	7 (2.5, 8.25)	23 (23, 31)	24 (6.5, 45.5)	13 (8, 18)
CHANT+ve, BFP+ve	51 (47, 58)	47.57 (41.17, 52.38)	1.71 (1.66, 1.84)	1.57 (1.53, 1.61)	25.92 (23.38, 32.41)	28.33 (23.29, 32.38)	0.92 (0.91, 1.04)	0.95 (0.85, 1.04)	0.92 (0.88, 1.04)	0.86 (0.82, 0.91)	0.50	4.54	8 (4, 8.75)	26 (19, 35.5)	43 (11.5, 47)	16 (12, 21.5)
CHANT+ve, BFP+ve, DN4-I+ve	53 (41, 58)	46.94 (41.17, 52.24)	1.72 (1.63, 1.85)	1.58 (1.53, 1.62)	25.21 (21.61, 30.11)	28.33 (23.29, 32.38)	0.91 (0.91, 1.02)	0.95 (0.85, 1.04)	0.92 (0.88, 1.04)	0.86 (0.80, 0.90)	0.17	5.00	8 (6, 9)	27 (19, 34)	43.5 (24, 47)	17 (11, 25)

	CD4 count (Median, IQR)	**Viral load (copies/ml) Median, IQR**	**Current antiretroviral drugs**	**Legends for drug names**
London cohort	589.5 (435.5, 765)	11205.5 (114, 192449)	DRV, RTV = 3%; ABC, 3TC, NVP = 3%; FTC, TFV, TAZ, RTV, EVG = 3%; EFV, FTC, TFV = 23%; TFV, FTC, TAZ, RTV = 17%; LPV, RTV = 3%; DRV, RTV, MVC = 3%; FTC, TFV, RPV = 7%; FTC, TFV, DRV, RTV = 3%; ETR, ABC, 3TC = 3%; TFV, FTC, NVP = 3%; ABC, 3TC, EFV = 3%; ABC, 3TC, DRV, RTV = 3%; FTC, TFV, RAL, EFV = 3%; RAL, ETR, RTV, DRV = 3%; TAZ, RAL, RTV, NVP = 3%	DRV = darunavir; RTV = ritonavir; ABC = Abacavir; 3TC = lamivudine; NVP = nevirapine; FTC = emtricitabine; TFV = tenofovir; TAZ = atazanavir; EVG = elvitegravir; EFV = efavirenz; LPV = lopinavir; MVC = maraviroc; RPV = rilpivirine; ETR = etravirine; RAL = raltegravir;
Johannesburg cohort	485 (296, 722)	Not available	D4T/3TC/EFV = 17%; TDF/3TC/LPVr = 9%; TDF/3TC/EFV = 35%; TDF/FTC/EFV = 4%; ABC/3TC/LPVr = 2%; AZT/3TC/EFV = 13%; ABC/3TC/EFV = 4%; TDF/3TC/NVP = 2%; AZT/3TC/LPVr = 9%	